BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I dose escalation study to determine the safety, pharmacokinetics and
pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with
advanced colorectal cancer who have received no more than 2 prior regimens for metastatic
colorectal cancer.